BioLineRx (NASDAQ:BLRX) Upgraded at StockNews.com

StockNews.com upgraded shares of BioLineRx (NASDAQ:BLRX) to a sell rating in a research report released on Wednesday morning.

Separately, HC Wainwright reissued a buy rating and issued a $21.00 target price on shares of BioLineRx in a report on Tuesday.

BioLineRx Price Performance

BLRX opened at $1.12 on Wednesday. The stock’s 50 day simple moving average is $1.20 and its 200 day simple moving average is $1.46. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.53 and a quick ratio of 1.86. BioLineRx has a 1 year low of $0.81 and a 1 year high of $2.53. The firm has a market cap of $81.13 million, a price-to-earnings ratio of -1.24 and a beta of 1.40.

BioLineRx (NASDAQ:BLRX) last issued its quarterly earnings data on Tuesday, March 26th. The biotechnology company reported ($0.15) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.07. The business had revenue of $4.80 million during the quarter, compared to the consensus estimate of $0.17 million. During the same quarter in the prior year, the business posted ($0.09) earnings per share. As a group, analysts predict that BioLineRx will post -0.91 earnings per share for the current year.

Institutional Trading of BioLineRx

Several hedge funds have recently bought and sold shares of BLRX. Renaissance Technologies LLC lifted its position in shares of BioLineRx by 278.0% in the fourth quarter. Renaissance Technologies LLC now owns 257,900 shares of the biotechnology company’s stock valued at $152,000 after acquiring an additional 189,678 shares in the last quarter. Atria Wealth Solutions Inc. bought a new stake in shares of BioLineRx in the 1st quarter valued at approximately $178,000. Envestnet Asset Management Inc. bought a new stake in shares of BioLineRx in the 1st quarter valued at approximately $88,000. LPL Financial LLC raised its holdings in shares of BioLineRx by 152.7% in the fourth quarter. LPL Financial LLC now owns 117,710 shares of the biotechnology company’s stock worth $69,000 after buying an additional 71,134 shares during the period. Finally, PVG Asset Management Corp purchased a new stake in shares of BioLineRx in the fourth quarter worth approximately $97,000. Institutional investors own 1.56% of the company’s stock.

About BioLineRx

BioLineRx Ltd., a pre-commercial-stage biopharmaceutical company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia.